NCT04929912Recruiting
Electroporation for Cancer Treatment Real World Registry
Source: ClinicalTrials.gov · Last updated 29 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 10 Jun 2021
- Start date
- 24 Jun 2021
- Primary completion date
- 24 Dec 2026
- Lead sponsor
- Mirai Medical
- Diseases
- Childhood cancers
- NCT number
- NCT04929912
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 24 Jun 2021 to the primary completion date, 24 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Any patient who has been treated using Calcium Electroporation
- Any patient who has been treated using Electrochemotherapy
- Patients must be mentally capable of understanding the information given
- Patients must give written informed consent.
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal London Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.